AVROBIO INC (AVRO) Stock Price & Overview
NASDAQ:AVRO • US05455M1009
The current stock price of AVRO is 1.4 USD. Today AVRO is down by -1.41%. In the past month the price increased by 1.45%. In the past year, price increased by 52.14%.
AVRO Key Statistics
- Market Cap
- 62.846M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.16
- Dividend Yield
- N/A
AVRO Stock Performance
AVRO Stock Chart
AVRO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AVRO. When comparing the yearly performance of all stocks, AVRO is one of the better performing stocks in the market, outperforming 92.57% of all stocks.
AVRO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVRO. No worries on liquidiy or solvency for AVRO as it has an excellent financial health rating, but there are worries on the profitability.
AVRO Earnings
AVRO Forecast & Estimates
8 analysts have analysed AVRO and the average price target is 2.04 USD. This implies a price increase of 45.71% is expected in the next year compared to the current price of 1.4.
AVRO Groups
Sector & Classification
AVRO Financial Highlights
Over the last trailing twelve months AVRO reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 49.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 32.82% | ||
| ROE | 34.11% | ||
| Debt/Equity | 0 |
AVRO Ownership
AVRO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.19 | 402.577B | ||
| AMGN | AMGEN INC | 16.11 | 203.574B | ||
| GILD | GILEAD SCIENCES INC | 16.43 | 181.247B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.66 | 125.079B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 81.897B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.52 | 42.495B | ||
| INSM | INSMED INC | N/A | 30.048B | ||
| BIIB | BIOGEN INC | 11.5 | 27.955B | ||
| NTRA | NATERA INC | N/A | 27.865B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.84 | 23.875B | ||
| MRNA | MODERNA INC | N/A | 22.105B | ||
| EXAS | EXACT SCIENCES CORP | 339.75 | 19.738B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.736B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AVRO
Company Profile
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of various HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-05 for the treatment of neuronopathic mucopolysaccharidosis type II (MPS-II) or Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.
Company Info
IPO: 2018-06-21
AVROBIO INC
100 Technology Square, 6th Floor
Cambridge MASSACHUSETTS 02139 US
CEO: Geoff MacKay
Employees: 78
Phone: 16179148420
AVROBIO INC / AVRO FAQ
What does AVRO do?
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of various HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-05 for the treatment of neuronopathic mucopolysaccharidosis type II (MPS-II) or Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.
What is the stock price of AVROBIO INC today?
The current stock price of AVRO is 1.4 USD. The price decreased by -1.41% in the last trading session.
Does AVROBIO INC pay dividends?
AVRO does not pay a dividend.
How is the ChartMill rating for AVROBIO INC?
AVRO has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for AVROBIO INC?
AVROBIO INC (AVRO) operates in the Health Care sector and the Biotechnology industry.